Related Experiment Video
Updated: Oct 10, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
Peter H J Slootbeek1,2, Iris S H Kloots1, Minke Smits1
1Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Medical Oncology, Nijmegen, The Netherlands.
Background:
Molecular tumour boards (MTB) optimally match oncological therapies to patients with genetic aberrations. Prostate cancer (PCa) is underrepresented in these MTB discussions. This study describes the impact of routine genetic profiling and MTB referral on the outcome of PCa patients in a tertiary referral centre.
Methods:
All PCa patients that received next-generation sequencing results and/or were discussed at an MTB between Jan 1, 2017 and Jan 1, 2020 were included. Genetically matched therapies (GMT) in clinical trials or compassionate use were linked to actionable alterations. Response to these agents was retrospectively evaluated.
Results:
Out of the 277 genetically profiled PCa patients, 215 (78%) were discussed in at least one MTB meeting. A GMT was recommended to 102 patients (47%), of which 63 patients (62%) initiated the GMT. The most recommended therapies were PARP inhibitors (n = 74), programmed death-(ligand) 1 inhibitors (n = 21) and tyrosine kinase inhibitors (n = 19). Once started, 41.3% had a PFS of ≥6 months, 43.5% a PSA decline ≥50% and 38.5% an objective radiographic response.
Conclusion:
Recommendation for a GMT is achieved in almost half of the patients with advanced prostate cancer, with GMT initiation leading to durable responses in over 40% of patients. These data justify routine referral of selected PCa patients to MTB's.
Insights
Molecular tumour boards (MTB) improve outcomes for prostate cancer (PCa) patients by matching genetic aberrations to targeted therapies. Routine genetic profiling and MTB referral led to durable responses in over 40% of patients receiving genetically matched therapies.
Area of Science:
- Oncology
- Genetics
- Precision Medicine
Background:
- Molecular tumour boards (MTB) are crucial for matching oncological therapies to patients with genetic aberrations.
- Prostate cancer (PCa) has been underrepresented in MTB discussions.
- This study investigates the impact of routine genetic profiling and MTB referral on PCa patient outcomes.
Purpose of the Study:
- To evaluate the effectiveness of routine genetic profiling and MTB referral for prostate cancer patients.
- To determine the rate of genetically matched therapy (GMT) recommendations and initiation in PCa.
- To assess the response rates to GMT in PCa patients.
Main Methods:
- Retrospective analysis of PCa patients who received next-generation sequencing and/or MTB discussion between 2017-2020.
- Identification of actionable alterations and linkage to GMT (clinical trials or compassionate use).
- Evaluation of patient response to GMT, including progression-free survival, PSA decline, and radiographic response.
Main Results:
- 215 out of 277 (78%) genetically profiled PCa patients were discussed in an MTB.
- A GMT was recommended for 102 patients (47%), with 63 (62%) initiating therapy.
- Among patients who started GMT, 41.3% achieved ≥6 months progression-free survival, 43.5% had ≥50% PSA decline, and 38.5% showed objective radiographic response.
Conclusions:
- Genetically matched therapies are recommended for nearly half of advanced prostate cancer patients.
- GMT initiation results in durable responses in over 40% of treated PCa patients.
- Routine referral of selected PCa patients to MTBs is justified based on these outcomes.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers